Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics

This study aimed to analyze and discuss the biomarkers of PEGylated liposomal doxorubicin (PLD) injection-induced hypersensitivity reactions (HSRs) in advanced breast cancer patients. Fourteen patients from Sun Yat-sen Memorial Hospital were included in the study between April 15th, 2020 and April 1...

Full description

Bibliographic Details
Main Authors: Wei Zhuang, Xiuping Lai, Qingxiu Mai, Suiwen Ye, Junyi Chen, Yanqiong Liu, Jingshu Wang, Siming Li, Yanqing Huang, Tao Qin, Hai Hu, Junyan Wu, Herui Yao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
breast cancer
PEGylated liposomal doxorubicin
hypersensitivity reaction
l-histidine
metabolomics
toxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.827446/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.827446/full

Similar Items